Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation (deLTa)

Project: Research project

Description

The purpose of this study is to look at the safety of:
1. Taking a specific combination of immunosuppressant drugs after liver transplantation
2. Receiving one of three different doses of donor reactive Tregs while taking this specific
combination of drugs
One goal of this study is to see if a specific combination of immunosuppressants that has been
designed to increase Treg numbers is safe. None of the immunosuppressants in this study are
experimental but the combination of medications is new. Patients in this study will receive the
new combination of medications.
Later in the study, white blood cells will be removed from study participants’ blood. This can be
done by drawing blood and then taking out the white blood cells in the lab, or by using a
procedure called “leukapheresis.” These cells will be processed to make the donor reactive Treg
infusion that will be given back to the transplant recipient. Three increasing doses of Tregs will
be tested for safety in this study.
The study team will collect information about the immunosuppressants and any problems that
may arise. Blood and liver biopsy samples will be collected to learn more about how cells
behave when using the study immunosuppressants after liver transplantation. For subjects
receiving Tregs, the dose of donor reactive Tregs will be recorded and participants will be
monitored for side effects. Additional laboratory testing will be done to see if the Tregs that were
given can be found in the blood and liver samples.
Some of the tests performed on samples will include looking at your genes (genetic testing).
Genetic tests look at an individual’s inherited characteristics, found in DNA, which is present in
every cell in the body. DNA contains information needed to construct and operate the human
body. For example, researchers may want to see whether a gene might be switched “on” or “off”
at the time of rejection or whether the Tregs that are given switch genes on or off. The study
team hopes to understand what gene patterns might be linked to good liver transplant
outcomes.
StatusActive
Effective start/end date6/1/175/31/20

Funding

  • University of California, San Francisco (10526sc//5U01AI110658-05)
  • National Institute of Allergy and Infectious Diseases (10526sc//5U01AI110658-05)

Fingerprint

Isoantigens
Regulatory T-Lymphocytes
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Liver Transplantation
Tissue Donors
Liver
Leukocytes
Switch Genes
Genes
Leukapheresis
Safety
DNA
Genetic Testing
Drug Combinations
Research Personnel
Biopsy